A large-scale clinical trial from the University of Auckland provides new clarity for parents regarding common medications for infants. The study examined nearly 4,000 babies to determine if acetaminophen or ibuprofen use during the first year of life increases the risk of developing eczema or bronchiolitis.
Researchers found no statistically significant link between these medications and the development of these health conditions. Both drugs showed high safety profiles for pain and fever management during infancy with no serious side effects reported among the participants.
This trial represents the largest clinical research project involving children ever conducted in New Zealand. By utilizing a randomized controlled structure, the team established a reliable baseline for infant medical safety.
The study is part of the long-term PIPPA Tamariki project, which continues to monitor these children until they reach age six. Ongoing observation will allow researchers to assess potential connections between early medication use and conditions like asthma, ADHD, or autism as the participants grow older.
These findings offer evidence for parents and healthcare providers to rely on established pain management protocols with increased confidence. Further reports are expected as the children progress through developmental milestones in the coming years.